Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea

Autor: Jong Han Yu, Soo-Hyeon Lee, Sung Won Lim, Jang Ho Cho, Song Ee Park, Jin Seok Ahn, Yu Jin Kim, Young-Hyuck Im, Hee Kyung Kim, Ji-Yeon Kim, Hansang Lee, Yeon Hee Park
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
Cancer Research
Receptor
ErbB-2
medicine.medical_treatment
Tertiary Care Centers
0302 clinical medicine
Surgical oncology
Antineoplastic Combined Chemotherapy Protocols
Practice Patterns
Physicians'
Response rate (survey)
Hormone receptor positive
Palliative Care
Hazard ratio
Middle Aged
Metastatic breast cancer
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Progression-Free Survival
Treatment Outcome
Receptors
Estrogen
030220 oncology & carcinogenesis
Practice Guidelines as Topic
Population study
Female
Guideline Adherence
Receptors
Progesterone
Research Article
Adult
medicine.medical_specialty
Adolescent
Breast Neoplasms
lcsh:RC254-282
Young Adult
03 medical and health sciences
Internal medicine
Republic of Korea
Genetics
medicine
Humans
Endocrine system
Chemotherapy
Proportional Hazards Models
Retrospective Studies
Premenopausal
business.industry
Guideline
medicine.disease
030104 developmental biology
Premenopause
business
Zdroj: BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Cancer
ISSN: 1471-2407
DOI: 10.1186/s12885-018-5258-9
Popis: Background In this study, we observe the patterns initial palliative treatment for premenopausal patients with HR-positive/HER2-negative MBC and determine if nonadherence to clinical guidelines are associated with worse clinical outcomes in terms of progression-free survival (PFS) and overall survival (OS) in the South Korean population. Methods A retrospective review was performed for premenopausal patients diagnosed with HR-positive/HER2-negative MBC between October 1997 and May 2016 who received palliative systemic treatments at a large tertiary medical center. Survival outcomes were analyzed according to the palliative treatment received prior to disease progression. Results The review identified a total of 272 premenopausal patients meeting study criteria, whose median age was 39 years. Endocrine therapy was the initial treatment in 137 patients (Group 1) with chemotherapy as initial treatment in 135 patients. In the latter group, chemotherapy was continued in 78 patients (Group 2), whereas chemotherapy was switched to endocrine treatment in 57 patients prior to any disease progression (Group 3). Both PFS and OS were significantly longer for chemotherapy-endocrine therapy (median PFS 18.2 months and OS 85.2 months) than for chemotherapy-alone (median PFS 12.6 months and OS 45.5 months) or endocrine therapy-alone (median PFS 7.0 months and OS 57.3 months) (all p values
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje